MICA: The Newcastle Proximity Laboratory
Lead Research Organisation:
Newcastle University
Department Name: Translational and Clinical Res Institute
Abstract
The introduction of new scientific methods has shown that many diseases are much more heterogeneous than originally believed and that differences between cases can have a marked influence on the way that patients respond favourably to treatment. This has led to the concept of "stratified" medicine in which treatment is adjusted to meet the needs of individual patients. This approach ensures that treatment is only given to patients who are likely to respond and has both clinical and economic benefits, as unnecessary toxicity will be avoided and expensive new therapies are conserved.
The introduction of stratified medicine requires the development of diagnostic techniques which can be used in clinical practice. In order for a new test to be adopted it has to be validated using "real-life" samples and adapted so that it can be used reliably in routine clinical laboratories. For many tests this requires input from experts in Cellular Pathology. However, in recent years, due largely to service pressures, many clinical and non-clinical specialists in this discipline have been unable to dedicate time to maintaining their knowledge in Molecular Pathology or to undertake research themselves.
Our bid responds to the three areas for need identified by the MRC in order to ensure that the development of new diagnostic tests keeps pace with the demands of stratified medicine; restoration of the proximity between clinical and research activity; development of a clear path between discovery science and clinical application and addressing the training needs of laboratory staff.
PROXIMITY
We will establish a "Proximity Laboratory" in a busy NHS service department, which is adjacent to the University Medical Faculty, involving both University and clinical staff. Three satellite laboratories will be established in the Medical School and the Transplant Institute (Freeman Hospital), to provide a well-equipped training and research environment close to the discovery laboratories.
PATH
Initial projects undertaken in the Proximity Laboratory will build on current expertise in treatment stratification in the fields of liver, inflammatory bowel and mitochondrial disease and childhood cancer. An advisory panel will be established to assist research teams in the development of new diagnostic approaches and 2-4 projects per year will be selected for support to generate pilot data to underpin applications for validation by funding programmes such as those operated by the NIHR or MRC. Funding by the Proximity Laboratory will generally be for 1-2 years and monitored to prevent stagnation. Links with the Newcastle Diagnostic Evaluation Co-operative (DEC) will assist with the adoption of promising new diagnostic approaches by commercial partners, thereby helping to ensure the maximum impact on clinical practice.
In addition to the support given to biomedical projects the Proximity Laboratory will also promote research activity in the fields of biomedical engineering and computing science. Biomedical engineering projects will focus on the need to improve methods for handling small samples in response to a trend towards the use of minimally invasive biopsy techniques and will involve collaboration with groups based in our established nanotechnology laboratory (NanoLAB) and Diagnostic and Therapeutic Technologies Group. Collaborations will also be established with computer scientists in the Interdisciplinary Computing and Complex BioSystems (ICOS) research group in Newcastle University in order to develop new ways to present complex datasets in a way accessible for clinical application.
PEOPLE
Training in Molecular Pathology will be offered through a range of distance learning opportunities, up to the level of a Master's degree. In addition undergraduates will be encouraged to enter the speciality by offering bursaries for intercalated degrees. This approach will both increase capacity and help to augment the skills of existing staff
The introduction of stratified medicine requires the development of diagnostic techniques which can be used in clinical practice. In order for a new test to be adopted it has to be validated using "real-life" samples and adapted so that it can be used reliably in routine clinical laboratories. For many tests this requires input from experts in Cellular Pathology. However, in recent years, due largely to service pressures, many clinical and non-clinical specialists in this discipline have been unable to dedicate time to maintaining their knowledge in Molecular Pathology or to undertake research themselves.
Our bid responds to the three areas for need identified by the MRC in order to ensure that the development of new diagnostic tests keeps pace with the demands of stratified medicine; restoration of the proximity between clinical and research activity; development of a clear path between discovery science and clinical application and addressing the training needs of laboratory staff.
PROXIMITY
We will establish a "Proximity Laboratory" in a busy NHS service department, which is adjacent to the University Medical Faculty, involving both University and clinical staff. Three satellite laboratories will be established in the Medical School and the Transplant Institute (Freeman Hospital), to provide a well-equipped training and research environment close to the discovery laboratories.
PATH
Initial projects undertaken in the Proximity Laboratory will build on current expertise in treatment stratification in the fields of liver, inflammatory bowel and mitochondrial disease and childhood cancer. An advisory panel will be established to assist research teams in the development of new diagnostic approaches and 2-4 projects per year will be selected for support to generate pilot data to underpin applications for validation by funding programmes such as those operated by the NIHR or MRC. Funding by the Proximity Laboratory will generally be for 1-2 years and monitored to prevent stagnation. Links with the Newcastle Diagnostic Evaluation Co-operative (DEC) will assist with the adoption of promising new diagnostic approaches by commercial partners, thereby helping to ensure the maximum impact on clinical practice.
In addition to the support given to biomedical projects the Proximity Laboratory will also promote research activity in the fields of biomedical engineering and computing science. Biomedical engineering projects will focus on the need to improve methods for handling small samples in response to a trend towards the use of minimally invasive biopsy techniques and will involve collaboration with groups based in our established nanotechnology laboratory (NanoLAB) and Diagnostic and Therapeutic Technologies Group. Collaborations will also be established with computer scientists in the Interdisciplinary Computing and Complex BioSystems (ICOS) research group in Newcastle University in order to develop new ways to present complex datasets in a way accessible for clinical application.
PEOPLE
Training in Molecular Pathology will be offered through a range of distance learning opportunities, up to the level of a Master's degree. In addition undergraduates will be encouraged to enter the speciality by offering bursaries for intercalated degrees. This approach will both increase capacity and help to augment the skills of existing staff
Technical Summary
Building on strengths in discovery science we will provide world-class training to a new generation of molecular pathologists, producing a step-change in the delivery of precision medicine. We will prioritise the development of in vitro diagnostics in chronic and rare diseases, ensuring pull-through to industry and clinical practice using well established links with the Newcastle NIHR DEC and our recent Proximity to Discovery Award. Our technical focus will be solving challenges posed by multiparameter analysis of microbiopsies, working with engineers in the Newcastle nanoLAB and Diagnostics & Therapeutic Technologies group. We will develop methods for the data analysis, interpretation and integration of results into clinically useful formats through collaboration with our Interdisciplinary Computing & Complex BioSystems research group and provide high quality samples for research partners using our established Biobank. Our main base will be in an NHS Pathology Department, ensuring close interaction with clinical pathologists. Building on experience gained with developing our Wellcome Trust Translational Medicine & Therapeutics Programme we will extend our e-learning Masters in Translational Medicine & Therapeutics to include a strand on Molecular Pathology, linked to the development of intercalated degrees for medical students to promote capacity building. We shall sit within infrastructure at Newcastle that includes the NIHR BRC in Ageing & Age-Related Chronic Disease, the NIHR BRU in Lewy Body Dementia, the MRC Centre for Brain Ageing & Vitality, the Wellcome Trust Centre for Mitochondrial Research, the MRC Centre for Neuromuscular Disease, an NIHR Bioresource in Rare Diseases and an NIHR Blood and Transplant Research Unit in Organ Donation & Transplantation. Programme Grant awards support research into stratified medicine and the biology of liver, musculoskeletal, neuromuscular diseases and cancer, ensuring a supply of novel approaches for further development.
Planned Impact
Work conducted by the Newcastle node will have commercial value and patient benefit and provide training to develop a skilled workforce in Molecular Pathology.
COMMERCIAL VALUE AND PATIENT BENEFIT
The main purpose of the Proximity Laboratory is to facilitate the development of novel tests for use in stratified medicine. With improved knowledge of the molecular basis of many diseases there has been a sharp rise in the number of therapies directed at specific, molecularly defined, subgroups. This fragmentation of disease classification has led to a rise in the cost of treatment to compensate for a fall in the size of the target patient group. In order to ensure future financial sustainability it is essential that targeted therapies are only given to the group who will benefit. Precision in prescribing also has health benefits as patients are not exposed to unnecessary and potentially toxic therapy.
The development of fully validated assays for use as a companion diagnostic for an expensive new therapy will have a considerable market value, as long as there is an actionable outcome. Deploying new assays requires considerable investment in terms of quality control and product support. Under the current system these can only be efficiently provided by commercialisation. The node will work closely with commercial partners to maximise the chance that new assays will be made available for exploitation whilst ensuring a reasonable return for the associated intellectual property for further investment in research activity. In addition, the activity of the node is also expected to lead to new methods of sample handling. With the introduction of improved methods for treatment stratification there is an urgent need to ensure that successful biopsies are obtained in as many patients as possible. There is also a drive towards reducing sample size in order to reduce collateral damage to normal tissues- for example in neurosurgery. This leads to need to improve techniques for manipulating small samples in such a way as to minimise wastage. The outcome of collaborative research in the node with biomedical engineers is likely to lead to new approaches with commercial value in the medical sector and beyond- for example in animal based research and veterinary practice.
The introduction of a range of 'omics approaches to accurate disease stratification poses a considerable challenge for presenting data with rapid clinical utility. Teams using the Proximity Laboratory will have access to computer scientists based in the University's Interdisciplinary Computing and Complex BioSystems research group and have the opportunity to develop novel ways of presenting data which make them easy to interpret for the non-specialist, and therefore of greatly enhanced value in clinical practice.
The link between the development of new assays for treatment stratification or methods for sample handling in the Proximity Laboratory and commercial development is unlikely to be direct therefore the timescale in most cases is expected to be 3-5 years. The timescale is expected to be much shorter in the case of software development where further validation by, for example, the DEC or via downstream funding is less likely to be necessary.
TRAINING OF A SKILLED WORKFORCE
The existence of a well-trained workforce will be essential for the development of the UK as a base for innovation in molecular pathology. The Proximity Laboratory will provide a focus for a range of training initiatives aimed at promoting molecular pathology as a career choice for undergraduates and for improving the skills of trainees and established members of staff. There will also be opportunities for non-clinically qualified staff based in the NHS and the University to be exposed to new approaches and techniques to add to their portfolio.
COMMERCIAL VALUE AND PATIENT BENEFIT
The main purpose of the Proximity Laboratory is to facilitate the development of novel tests for use in stratified medicine. With improved knowledge of the molecular basis of many diseases there has been a sharp rise in the number of therapies directed at specific, molecularly defined, subgroups. This fragmentation of disease classification has led to a rise in the cost of treatment to compensate for a fall in the size of the target patient group. In order to ensure future financial sustainability it is essential that targeted therapies are only given to the group who will benefit. Precision in prescribing also has health benefits as patients are not exposed to unnecessary and potentially toxic therapy.
The development of fully validated assays for use as a companion diagnostic for an expensive new therapy will have a considerable market value, as long as there is an actionable outcome. Deploying new assays requires considerable investment in terms of quality control and product support. Under the current system these can only be efficiently provided by commercialisation. The node will work closely with commercial partners to maximise the chance that new assays will be made available for exploitation whilst ensuring a reasonable return for the associated intellectual property for further investment in research activity. In addition, the activity of the node is also expected to lead to new methods of sample handling. With the introduction of improved methods for treatment stratification there is an urgent need to ensure that successful biopsies are obtained in as many patients as possible. There is also a drive towards reducing sample size in order to reduce collateral damage to normal tissues- for example in neurosurgery. This leads to need to improve techniques for manipulating small samples in such a way as to minimise wastage. The outcome of collaborative research in the node with biomedical engineers is likely to lead to new approaches with commercial value in the medical sector and beyond- for example in animal based research and veterinary practice.
The introduction of a range of 'omics approaches to accurate disease stratification poses a considerable challenge for presenting data with rapid clinical utility. Teams using the Proximity Laboratory will have access to computer scientists based in the University's Interdisciplinary Computing and Complex BioSystems research group and have the opportunity to develop novel ways of presenting data which make them easy to interpret for the non-specialist, and therefore of greatly enhanced value in clinical practice.
The link between the development of new assays for treatment stratification or methods for sample handling in the Proximity Laboratory and commercial development is unlikely to be direct therefore the timescale in most cases is expected to be 3-5 years. The timescale is expected to be much shorter in the case of software development where further validation by, for example, the DEC or via downstream funding is less likely to be necessary.
TRAINING OF A SKILLED WORKFORCE
The existence of a well-trained workforce will be essential for the development of the UK as a base for innovation in molecular pathology. The Proximity Laboratory will provide a focus for a range of training initiatives aimed at promoting molecular pathology as a career choice for undergraduates and for improving the skills of trainees and established members of staff. There will also be opportunities for non-clinically qualified staff based in the NHS and the University to be exposed to new approaches and techniques to add to their portfolio.
Organisations
- Newcastle University (Collaboration, Lead Research Organisation)
- Engineering and Physical Sciences Research Council (Co-funder)
- AMLo Bioscience Ltd (Collaboration)
- Bone Cancer Research Trust (Collaboration)
- North Eastern Skin Research Fund (Collaboration)
- Newcastle upon Tyne Hospitals NHS Charity (Collaboration)
- Tissue Solutions UK (Collaboration)
- Leica UK Ltd (Collaboration)
- Human Technopole (Collaboration)
- Sir Bobby Robson Foundation (Collaboration)
- RedxPharma (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- LEICA BIOSYSTEMS (Collaboration)
- Bicycle Therapeutics (Collaboration)
- Wellcome Trust (Collaboration)
- Reece Innovation Ltd (Collaboration)
- Avacta Group (Collaboration)
- FIBROFIND LTD (Collaboration)
- QUEEN'S UNIVERSITY BELFAST (Collaboration)
- National Cancer Research Institute (NCRI) (Collaboration)
- Nascient ltd (Collaboration)
- Genentech, Inc (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Rosetrees Trust (Collaboration)
- Cancer Research UK (Collaboration)
- AstraZeneca (United Kingdom) (Collaboration)
- INNOVATE UK (Collaboration)
- LIVErNORTH (Collaboration)
- Achilles Therapeutics Ltd (Collaboration)
- NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- Resolve Therapeutics, LLC (Collaboration)
- Children's Cancer and Leukaemia Group (CCLG) (Collaboration)
- UK NEQAS CPT (Collaboration)
- Genomics England (Collaboration)
- 3Helix Inc (Collaboration)
- NewGene Ltd (Project Partner)
Publications
Zerti D
(2020)
Developing a simple method to enhance the generation of cone and rod photoreceptors in pluripotent stem cell-derived retinal organoids.
in Stem cells (Dayton, Ohio)
| Description | A pilot study to compare the RNA transcriptomic response of psoriatic skin to narrow-band UVB phototherapy in the morning and afternoon (PaCTS) |
| Amount | £10,974 (GBP) |
| Organisation | North Eastern Skin Research Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 06/2019 |
| Description | Confidence in Concept- The Development of a Near Infrared Sensor for the Intraoperative Identification of Tumour Margins. |
| Amount | £37,222 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 01/2018 |
| Description | Confidence in Concept- Validation of innate immunity proteins linked to pathogensis of necrotising enterocolitis |
| Amount | £18,245 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 02/2018 |
| Description | Confidence in Concept-Integrating gene expression profiling and multiplexed immunofluoresence to quanity the microenvironment of classical hodgkin lymphoma in different age groups |
| Amount | £36,212 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 07/2018 |
| Description | Functional and genomic characterisation of ultraviolet-B on involved and uninvolved psoriatic skin: application towards understanding of environmental stress effects on ageing and cancer risk. |
| Amount | £118,487 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2021 |
| Description | Funding for Dr Gaurav Dhawan, Clinical Research Fellow |
| Amount | £46,412 (GBP) |
| Organisation | Barts Health NHS Trust |
| Department | NIHR Biomedical Research Unit |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 08/2018 |
| Description | Immune-mediated Inflammatory Disease Biobanks in the UK (IMIDBio-UK) |
| Amount | £2,100,000 (GBP) |
| Funding ID | MR/R014191/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 08/2021 |
| Description | MRC Target Consortium Agreement |
| Amount | £2,169,447 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2017 |
| Description | NIHR Research Capability Funding |
| Amount | £105,844 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 01/2019 |
| Description | Newcastle/Genentech collaboration |
| Amount | £0 (GBP) |
| Funding ID | Contract in final stages of negotiation contract amount is commercially sensitive information |
| Organisation | Genentech, Inc |
| Sector | Private |
| Country | United States |
| Start | 04/2017 |
| End | 03/2018 |
| Description | Pancreas Tissue Bank with Linked Clinical Data for the study of Diabetes Pathogenesis |
| Amount | £2,100,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 08/2021 |
| Description | Personalised ultraviolet B (UVB) treatment of psoriasis through biomarker integration with computational modelling of psoriatic plaque resolution(2016 Interdisciplinary Prize Runner-Up - ST) |
| Amount | £250,000 (GBP) |
| Funding ID | M651 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2017 |
| End | 06/2020 |
| Description | Small Grant: A pilot study to compare the RNA transcriptomic response of psoriatic skin to narrow-band UVB phototherapy in the morning and afternoon (PaCTS) |
| Amount | £9,914 (GBP) |
| Organisation | British Skin Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 05/2020 |
| Description | Sponsorship from Eli Lilly UK |
| Amount | £5,280 (GBP) |
| Organisation | Eli Lilly & Company Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 06/2021 |
| Description | Collaboration agreement with Reece Innovation Centre Limited |
| Organisation | Reece Innovation Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The Node's Bioengineering strand will work with Reece to: ? - Miniaturise existing near infrared (NIR) sensing technology into a hand held device suitable for direct, real time intraoperative tumour margin detection; and ? - Conjugate a uPAR-specific antibody to a NIR-responsive fluorophore to produce a human carcinoma cell specific "contrast reagent"; and ? - Use the miniaturised NIR sensor in combination with the contrast reagent to selectively identify human colorectal carcinoma cells in culture and in histological preparations. |
| Collaborator Contribution | Reece Innovation will provide £31,500 in-kind funding. |
| Impact | The partnership with Reece began in February 2017 and is still in the early stages of development. |
| Start Year | 2017 |
| Description | Collaboration with Belfast/CRUK Accelerator Award |
| Organisation | Queen's University Belfast |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Queen's University Belfast, CRUK Accelerator programme and the Node jointly funded two students from Newcastle to complete a MSc in Belfast. The Node contributed £41,532 in fees and stipends for one student. |
| Collaborator Contribution | CRUK Accelerator and Queen's University contributed £41,532 in fees and stipends for the other student. |
| Impact | The two student's have completed their MSc courses with excellent marks and are considering applying to complete a PhD in pathology. |
| Start Year | 2016 |
| Description | Leica-supply of human tissue collaboration |
| Organisation | Leica UK Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The Trust will undertake to engage patients and facilitate donation of excess human tissues such as tonsillectomy samples to its Biobank, with proper recording of consent. The tissues will be processed by a defined protocol to a uniform high standard. Histopathological sections will be examined by a consultant pathologist who will authorize release of the human tissue to the Biobank. The Trust will audit the process and arrange for cost recovery when tissue is supplied to industry. The direct arrangement between an NHS Trust and Industrial partners will facilitate good governance, ensure high quality and avoid risks associated with third party suppliers. The MICA is currently in draft form but an agreement from both parties is expected. |
| Collaborator Contribution | Leica will receive the human tissue blocks and will handle the tissue under their HTA licence. The tissue will be used for quality control of existing products and for the development of new molecular pathology products. |
| Impact | The MICA is currently in draft form but the potential collaboration with Leica has led to the set up on a Biobank in the RVI Cellular Pathology department which will supply tissue to industry. |
| Start Year | 2017 |
| Description | MRC Target Consortium Agreement |
| Organisation | Medical Research Council (MRC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Newcastle is collaborating with Leeds University in a consortium agreement that also has links with Oxford, Birmingham, London, Bristol, Roche and X-Lab Ltd. |
| Collaborator Contribution | The collaborators are working together to to establish the MRC TARGET (Treatment According to Response in Giant cEll arTeritis) partnership, a multi-institution, multi-speciality partnership with a common purpose of reducing glucocorticoid toxicity and improving outcomes for patients with giant cell arteritis (GCA). They will fund the Proximity Lab work. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare |
| Start Year | 2017 |
| Description | NCRI- CM-Path Network |
| Organisation | National Cancer Research Institute (NCRI) |
| Department | CM-Path initiative |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Node PIs members of core educational work-streams and contribute to quality of pathological assessment within clinical trials and network development including regional engagement to improve sample processing for molecular testing. |
| Collaborator Contribution | Node partners also contribute to quality of pathological assessment within clinical trials and network development including regional engagement to improve sample processing for molecular testing. |
| Impact | Ongoing work to contribute to the quality of pathological assessment within clinical trials |
| Start Year | 2015 |
| Description | Node Proximity Lab Work- Bone Cancer Research Trust |
| Organisation | Bone Cancer Research Trust |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Node Proximity Lab completed work on the following project for a University researcher- - Preclinical evaluation of an MT1-MMP activated theranostic for Ewing's and steosarcoma |
| Collaborator Contribution | The Bone Cancer Trust funded the research. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare. |
| Start Year | 2017 |
| Description | Node Proximity Lab Work- CCLG |
| Organisation | Children's Cancer and Leukaemia Group (CCLG) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Node Proximity Lab completed work on a project for a University researcher-Characterisation of paediatric Hodgkin lymphoma: Pilot project to evaluate platforms to study HRS cells and the tumour microenvironment. |
| Collaborator Contribution | The research was funded by the CCLG. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare. |
| Start Year | 2016 |
| Description | Node Proximity Lab Work- NE Skin Research Fund LIVErNORTH |
| Organisation | LIVErNORTH |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Proximity Lab completed work on a project for the Node Director- evalute potential mechanisms of action in phototherapy for treatment of pruritus in primary biliary cholanggitis, also to investigate how it affects potential biomarkers and effects skin microbiome biomarkers. |
| Collaborator Contribution | The research was paid for by the NE Skin Research Fund LIVErNORTH. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare. |
| Start Year | 2016 |
| Description | Node Proximity Lab Work-CRUK |
| Organisation | Cancer Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Node Proximity Laboratory completed work for University researchers on the following projects: - Construction of neuroblastoma TMA for the CCLG tumour bank - Claspin mouse antibody optimisation |
| Collaborator Contribution | The researchers were funded by CRUK. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare. |
| Start Year | 2016 |
| Description | Node Proximity Lab Work-Wellcome Trust |
| Organisation | Wellcome Trust |
| Department | Wellcome Trust Bloomsbury Centre |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Node Proximity Laboratory completed work on the following items for a University researchers funded by the Wellcome Trust. -Optimisation of AXL and SIGLE antibodies to perform multiplex staining with CD123 and CD3. - The changes in DNA and RNA in familial tumours. - 3D reconstruction of Basal Cell Carcinomas - Integrative Genomic Profiling of inherited Cutaneous tumours. |
| Collaborator Contribution | The researcher was funded from a Wellcome trust grant. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare. |
| Start Year | 2016 |
| Description | NovoPath (CEPA) Biobank - - UK NEQAS CPT |
| Organisation | UK NEQAS CPT |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | NovoPath will be supplying high quality material to UK NEQAS CPT for their renowned and respected Cellular Pathology external quality assessment scheme. |
| Collaborator Contribution | UK NEQAS Cellular Pathology Technique (CPT) is a unique, world leading not-for-profit organisation and will use tissue provided by NovoPath to offer a comprehensive range of accredited programmes for all aspects of tissue diagnostics, for clinical and non-clinical laboratories and organisations. |
| Impact | No impact yet |
| Start Year | 2021 |
| Description | NovoPath (CEPA) Biobank - Achilles Therapeutics |
| Organisation | Achilles Therapeutics Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | NovoPath (CEPA) Biobank supplied T Cells/Tissue as requested by Achilles Therapeutics |
| Collaborator Contribution | This tissue was used to facilitate a Clinical Trial carried out by Achilles Therapeutics |
| Impact | No impact yet |
| Start Year | 2020 |
| Description | NovoPath (CEPA) Biobank - Fibrofind Ltd |
| Organisation | FibroFind Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | NovoPath has human biological material, which has been obtained on the basis of informed consent for which FibroFind Ltd is conducting research and/or tests with this material. |
| Collaborator Contribution | Fibrofind Ltd has developed a technology that allows prolonged use of functional precision-cut slices of various human organ tissues and apply their technology to liver, kidney and IPF lung PCS. |
| Impact | This is a Multi-disciplinary between NovoPath, Newcastle Fibrosis Research Group and Fibrofind Ltd |
| Start Year | 2020 |
| Description | NovoPath (CEPA) Biobank - Newcastle Fibrosis Research Group (NFRG) |
| Organisation | Newcastle University |
| Department | Newcastle Fibrosis Research Group |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The NovoPath (CEPA) Biobank allow NFRG access to a supply of good quality tissue for their further research into liver, lung, kidney, heart, skin and joints research. |
| Collaborator Contribution | NFRG uses NovoPath tissue to focus research on the discovery of molecules and molecular processes that regulate the formation, maintenance or degradation of scars in diseased solid organs. They particularly investigate the biology of myofibroblasts, these being the major cellular regulator of fibrosis. |
| Impact | No impact yet |
| Start Year | 2020 |
| Description | NovoPath (CEPA) Biobank - POCKitdx |
| Organisation | Innovate UK |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | NovoPath (CEPA) provided samples for POCKitdx to evaluate the diagnostic accuracy of a panel of biomarkers for LVO prediction. |
| Collaborator Contribution | POCKitdx analysed the plasma levels of D-dimer, OPN, OPG, GFAP, vWF, and ADAMTS13 in LVO vs non-LVO. Diagnostic performance was estimated by using blood biomarkers alone or in combination with NIHSS-derived stroke severity scales. |
| Impact | No impact yet |
| Start Year | 2020 |
| Description | NovoPath (CEPA) Biobank - Tissue Solutions |
| Organisation | Tissue Solutions UK |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | NovoPath provide Serum samples to be utilised by Tissue Solutions . |
| Collaborator Contribution | Tissue Solutions undertook a COVID 19 research project for which they used the NovoPath samples. |
| Impact | No impact yet |
| Start Year | 2020 |
| Description | NovoPath Proximity Lab - AMLo Bioscience Ltd |
| Organisation | AMLo Bioscience Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Proximity Lab to undertake comparative staining as requested. |
| Collaborator Contribution | AMBLor to produce an innovative prognostic test for early stage cutaneous melanoma. |
| Impact | • Validation of AMBLor diagnostic antibodies and manufactured kit (stability testing ongoing). • SOP production for automated immune-histochemical staining and analysis of AMBLor in non- ulcerated early stage melanomas. • Establishment and transfer of powered geographically distinct cohorts of AJCC stage I/II melanomas from UK, Spain, Australia and USA with AMBLor analysis completed in UK and Spanish cohorts. • Generation of data to verify additional clinical utility of AMBLor as a companion biomarker for adjuvant immunotherapy for AJCC stage II melanomas. • Acceptance and invited presentation of data at The European Association for Dermato-Oncology (Paris 2019, best talk prize awarded to P Lovat, ASC) (Chicago 2019), The International Melanoma Working Group (Lisbon 2019), and The Society for Melanoma Research (Salt Lake City 2019). • Public engagement including national and international press release (September 2019). |
| Start Year | 2019 |
| Description | NovoPath Proximity Lab - AVACTA (2021 - Still Active) |
| Organisation | Avacta Group |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | NovoPath to provide Fibroblast activation protein (FAP), Immunohistochemistry (IHC), DAB staining on a per sample basis for internal and external Avacta clinical trial samples. Processing, embedding and microtomy of Newcastle trial samples or staining of external sample blocks or slides. All staining will be reviewed and reported by a consultant Pathologist. |
| Collaborator Contribution | / |
| Impact | / |
| Start Year | 2021 |
| Description | NovoPath Proximity Lab - AmLo Biosciences Referral Service |
| Organisation | AMLo Bioscience Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | In partnership with CellPath at Newcastle-upon-Tyne Hospitals Trust (NuTH), AMLo has made its proprietary antibodies for AMBRA1 and loricrin available for a UKAS accredited referral service. |
| Collaborator Contribution | / |
| Impact | Clinicians in the NHS and private sector can now send melanoma patients' tissue biopsies to CellPath at Newcastle upon Tyne NHS Hospitals Trust for staining with AMBRA1 and loricrin antibodies to determine which early-stage non-ulcerated melanomas are genuinely at low risk of progression. |
| Start Year | 2021 |
| Description | NovoPath Proximity Lab - Genomics England - The 100,000 Genomes Project (2021 - Still Active) |
| Organisation | Genomics England |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Providing H&E Slides from 232 100k patient samples to assist in their Research Project |
| Collaborator Contribution | Providing H&E Slides from 232 100k patient samples to assist in their Research Project |
| Impact | / |
| Start Year | 2021 |
| Description | NovoPath Proximity Lab - Human Technopole |
| Organisation | Human Technopole |
| Country | Italy |
| Sector | Charity/Non Profit |
| PI Contribution | Providing support of H&E stained slides, FFPE blocks when available and associated diagnostic pathology reports. This work is in collaboration with a team of researchers based at University College London. We plan to ship original ±fresh H&E sections to the team in London to enable scanning and analysis of slides. To explore possibility of digital file transfer. |
| Collaborator Contribution | Prediction of outcome using digital pathology and artificial intelligence in inflammatory bowel disease |
| Impact | No outcomes as yet |
| Start Year | 2022 |
| Description | NovoPath Proximity Lab - Leica Biosystems |
| Organisation | Leica Biosystems |
| Department | Leica Microsystems (UK) |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Providing service for TMA Construction |
| Collaborator Contribution | Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. |
| Impact | / |
| Start Year | 2021 |
| Description | NovoPath Proximity Lab - North East Innovation Lab (NEIL) |
| Organisation | Newcastle upon Tyne Hospitals NHS Foundation Trust |
| Department | Integrated Covid Hub North East |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Working closely with the North East Innovation lab to look at ways of working collaboratively. Monthly meetings to discuss how to move forward together. |
| Collaborator Contribution | Working closely with the North East Innovation lab to look at ways of working collaboratively. Monthly meetings to discuss how to move forward together. |
| Impact | A smoother way of completing applications and a clearer route to gaining accreditation. |
| Start Year | 2023 |
| Description | NovoPath Proximity Lab - Quality in Organ Donation (QUOD) |
| Organisation | University of Oxford |
| Department | Quality in Organ Donation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Human pancreata samples from deceased donors without known pancreatic pathology (23-71 years, n=10) were processed and sectioned (4µm) within the NovoPath Proximity Lab. |
| Collaborator Contribution | Determine ß-cell CFTR mRNA and protein expression in situ in normal adult human pancreas |
| Impact | In situ CFTR mRNA expression in the unmanipulated pancreas is present in only a very small minority (<1%) of normal adult ß-cells. These data indicate insulin secretion is not mediated intrinsically by CFTR, signalling a need to focus on elucidation of exocrineendocrine interactions in human cystic fibrosis. |
| Start Year | 2019 |
| Description | NovoPath Proximity Lab - RedX Pharma |
| Organisation | RedxPharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | NovoPath receive biopsy samples from RedX and then undertake diagnostic testing before returning with analysis. |
| Collaborator Contribution | RedX is a biotech company and utilises the findings from NovoPath towards the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease. |
| Impact | No impact yet |
| Start Year | 2020 |
| Description | Proximity Lab work - 3Helix Inc partnership |
| Organisation | 3Helix Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | 3Helix funded NovoPath to establish CHPs as a reliable stain for evaluating fibrotic progression in liver disease to replace existing histochemical approaches such as trichrome staining or Picrosirius Red. |
| Collaborator Contribution | 3Helix developed Novel CHPs towards investigating this liver fibrosis project |
| Impact | Unknown at this time |
| Start Year | 2020 |
| Description | Proximity Lab work -North Eastern Skin Research Fund (NESRF) |
| Organisation | North Eastern Skin Research Fund |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Proximity Lab is carrying out research into the effect of UVB phototherapy in primary biliary cholangitis. |
| Collaborator Contribution | NESRF provides funding for Proximity Lab work. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare |
| Start Year | 2017 |
| Description | Proximity Lab work- Astrazeneca |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Node CI and the Proximity Lab are contributing to immunohistochemistry work for a COMPARE clinical trial. |
| Collaborator Contribution | AstraZeneca are funding work completed in the Proximity Lab. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare |
| Start Year | 2016 |
| Description | Proximity Lab work- Bicycle and Cancer Research UK |
| Organisation | Bicycle Therapeutics |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Node PIs are leading collaboration with Cambridge-based biotech company to provide real time molecular testing for application of a novel MT1-MMP biological agent in a phase I/II CRUK clinical trial for patients with Sarcoma and other eligible tumours. |
| Collaborator Contribution | Bicycle have provided funding and the biological agent for testing. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare |
| Start Year | 2017 |
| Description | Proximity Lab work- Bicycle and Cancer Research UK |
| Organisation | Cancer Research UK |
| Department | Cancer Research UK (CRUK) Oxford Centre |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Node PIs are leading collaboration with Cambridge-based biotech company to provide real time molecular testing for application of a novel MT1-MMP biological agent in a phase I/II CRUK clinical trial for patients with Sarcoma and other eligible tumours. |
| Collaborator Contribution | Bicycle have provided funding and the biological agent for testing. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare |
| Start Year | 2017 |
| Description | Proximity Lab work- Newcastle upon Tyne NHS Charities |
| Organisation | Newcastle upon Tyne Hospitals NHS Charity |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Proximity Lab is carrying out research work for a preclinical evaluation of an activated theranostic for Ewing's and Steosarcoma. |
| Collaborator Contribution | The NHS charity is funding the work in the Proximity Lab. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare |
| Start Year | 2016 |
| Description | Proximity Lab work- Rosetrees Trust |
| Organisation | Rosetrees Trust |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Node CI is CI of this stratified medicine study. The Node is a partner and is conducting biomarker replication and refinement on UV-treated psoriasis skin biopsies. |
| Collaborator Contribution | Rosetrees Trust is funding the Proximity Lab work. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare |
| Start Year | 2017 |
| Description | Proximity Lab work-Genentech |
| Organisation | Genentech, Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Node investigators are PI and Co-Is for this project that involved development of skin biomarkers for atopic eczema and their application to samples from a worldwide phase II study of lebrikizumab. |
| Collaborator Contribution | Genentech has paid for the work completed in the Proximity Laboratory |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare |
| Start Year | 2014 |
| Description | Proximity Lab work-Nascient |
| Organisation | Nascient ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Pre-clinical project to investigate Tenascin C as a potential theranostic in Sjögren's syndrome. Node investigator is a Co-I. |
| Collaborator Contribution | Nascient has paid for work completed in the Proximity Lab. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare |
| Start Year | 2016 |
| Description | Proximity Lab work-Resolve Theraputics |
| Organisation | Resolve Therapeutics, LLC |
| Country | United States |
| Sector | Private |
| PI Contribution | The Proximity Lab is carrying out an analysis of salivary gland biopsy samples for a clinical trial studying Primary Sjögren's syndrome. |
| Collaborator Contribution | Resolve Theraputics provides funding for Proximity Lab work. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare |
| Start Year | 2016 |
| Description | Prpximity Lab work-Sir Bobby Robson Foundation |
| Organisation | Sir Bobby Robson Foundation |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Collaborations with the Molecular Pathology Hub have enabled next generation sequencing of rare tumour samples. |
| Collaborator Contribution | Funding for work that is/ will be completed in the Proximity Lab. |
| Impact | The foundation stage research work carried out by the Proximity Lab can lead to new antibodies and diagnostic tests for stratified healthcare |
| Start Year | 2015 |
| Title | Evans M (CI) Cardiff University, Jones T (CI) Liverpool University, Robinson M (Co-investigator). Post-operative adjuvant treatment for HPV-positive tumours (PATHOS). |
| Description | The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols. The aim is to personalise treatment, based on disease biology (HPV status and pathology findings), to optimise patient outcomes. To demonstrate the non-inferiority of reducing the intensity of adjuvant treatment protocols in terms of overall survival in the reduced intensity treatment arms |
| Type | Support Tool - For Fundamental Research |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2015 |
| Development Status | Under active development/distribution |
| Impact | No reported impact at present |
| URL | https://clinicaltrials.gov/ct2/show/NCT02215265 |
| Title | Mehanna H (CI) University of Birmingham, Robinson M (Co-investigator). Phase III randomised controlled trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer (CompARE). |
| Description | The CompARE study has been set up to investigate which treatment is most effective for patients who have higher-risk oropharyngeal cancer. The purpose of this study is to consider using additional treatments in conjunction with standard chemoradiotherapy to increase cure rates of higher-risk oropharyngeal cancer. This will be done by adding surgery or immunotherapy or more chemotherapy or higher dose radiotherapy to the standard chemoradiotherapy. Immunotherapy is novel approach, which uses drugs that encourages the body's natural defence system, the immune system to attack cancer cells. |
| Type | Support Tool - For Fundamental Research |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Impact | No other impact reported at present |
| URL | https://www.birmingham.ac.uk/research/crctu/trials/compare/index.aspx |
| Title | Paleri V (CI), Robinson M (Co-investigator). MOSES pilot: head and neck squamous cell carcinoma unknown primary. Royal Marsden Hospital Trustees/Oracle funding. |
| Description | MOSES pilot: head and neck squamous cell carcinoma unknown primary. |
| Type | Support Tool - For Fundamental Research |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2022 |
| Development Status | Under active development/distribution |
| Impact | No impacts reported at present |
| Title | Rackley T and Evans M (Co-CIs), Velindre University NHS Trust, Robinson M (Co-investigator). PEARL: PET-based adaptive radiotherapy clinical trial. Cancer Research Wales Velindre Radiotherapy Charitable Funds (Moondance). |
| Description | PEARL: PET-based adaptive radiotherapy clinical trial. Cancer Research |
| Type | Support Tool - For Fundamental Research |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Impact | No impacts reported at present |
| URL | https://www.clinicaltrials.gov/ct2/show/NCT03935672 |
| Title | Shaw R (CI) Liverpool University, Robinson M (Co-investigator). Sodium valporate for the epigenetic reprogramming of high-risk oral epithelial dysplasia (SAVER). |
| Description | Sodium valporate for the epigenetic reprogramming of high-risk oral epithelial dysplasia (SAVER) |
| Type | Support Tool - For Fundamental Research |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2022 |
| Development Status | Under active development/distribution |
| Impact | No impacts reported at present |
| URL | https://pubmed.ncbi.nlm.nih.gov/34225765/ |
| Description | 'Molecular Diagnostics at Newcastle' |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Node recently took part in the Newcastle University NAHP Industry Month with a day-long event to showcase Node-related work. The title for the event was 'Molecular Diagnostics at Newcastle' and it was held on the 2nd March 2017. The purpose of the event was to bring industry together with the Node research community to identify potential collaboration opportunities around molecular diagnostics and image analysis. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.newcastlepathnode.org.uk/2017/03/molecular-diagnostics-newcastle-node-industry-event/ |
| Description | 3rd Joint Meeting of the Pathological Society and the Royal Society of Medicine 21-22 January 2020 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Society hosts a major conference twice a year with outstanding speakers on a range of topics from basic molecular pathology to diagnostic practice and provides a forum for investigators across the world to present their research.The Society also has a generous range of grants that it awards to its members including PhD studentships, scholarships and travel support. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.pathsoc.org |
| Description | 9th Digital Pathology & AI Congress: Europe |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Chris Kettle attended the Digital Pathology conference to actively interact with those providing digital pathology support and services. To explore further connections and highlight the NovoPath name. About the event - Hear 70+ presentations exploring the latest advances and applications of digital pathology. Learn how artificial intelligence and machine learning is being applied to primary diagnosis and clinical research. Discover how the image-based information environment is transforming the laboratory. Join an extended track featuring pharma and industry case studies. One of four extended panel discussions examines how innovation and AI continue to drive advances in pathology. The popular roundtables will provide an intimate setting for you and KOLs to discuss a variety of themes such as successful digital implementation strategies, toxicological pathology, and digital imaging in pharma. This meeting has a reputation for providing an outstanding networking experience. Plus, 45 leading hardware and software providers will be on hand to show you the very latest technology. |
| Year(s) Of Engagement Activity | 2008,2022 |
| URL | https://www.global-engage.com/event/digital-pathology-nhs/ |
| Description | A talk or presentation - Seminar Workshop 'Total Tissue Diagnostics' Megan Hamilton, Total Tissue Diagnostics. February 2023. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Presentation around the portfolio of Total Tissue Diagnostics and services provided. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Attendance USCAP 1009th Annual Meeting 2020 'Eyes on you' |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Conference including Major Advances in the Diagnosis and Management of GI and Liver Diseases, short courses, interactive microscopy courses, evening specialty conferences, hot topics, the Timely Topics lecture on CRISPR Technology, and a highly prestigious presentation, Killer on the loose? Precursor escape and ovarian cainogenesis |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.xcdsystem.com/uscap/program/2020/index. |
| Description | Attendance at Node Industry workshop and Director's meeting in Manchester |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | In June 2017, the Node Director's and project manager attended a Node network meeting hosted by the Manchester Node. This meeting included discussions on joint activities in training, health economics and bioinformatics as well updates on industry engagement and sustainability. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Bioimaging/bioinformatics/machine learning |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was a 2hr workshop which would help shape our bid for strategic investment in this area. This opportunity helped us to learn more about how digital and computational pathology / tissue scanning fits in with research / practice. We wanted very much to understand what digital scanning, deep learning/AI and image analysis services we could bring to Newcastle, and how we could develop our services to keep pace with future demands. This invite enabled all attendees to engage with this process and help bring together investigators and collaborators to discuss future directions. The outcome of the meeting was well attended and there was clear enthusiasm in taking this forward. |
| Year(s) Of Engagement Activity | 2020 |
| Description | CM Path Industry Day-October 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Node attended a part funded a CM Path Industry Day in October 2016. The programme for the day involved presentations around molecular diagnostics, the pharmaceutical industry and the adoption of new technologies in the NHS. It was well attended by industrial representatives and healthcare professionals. The event has led to plans for future activity between the Node and CM Path. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.ncri.org.uk/wp-content/uploads/2016/09/CM-Path-Industry-Engagement-Day-5th-October-2016.p... |
| Description | Commercial Enterprise Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | The objective of the workshop was to develop a standard and structured approach whereby we pulled information together about the proposed business idea, the market we are moving into, our financial projections and most importantly the recommendations for the next steps. During this 2 hour workshop we looked to focus on the key products or services that we feel could drive commercial value. Facilitated by the Director for Enterprise and Business Development, 2 x presentations were delivered triggering good interaction by attendees and subsequently embedded within the Node Business Plan which was submitted for approval at the end of March 2020. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Diagnosis Matters Event |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | The North East and North Cumbria (NENC) Academic Health Sciences Network (AHSN) working with Voice North held a 'Diagnosis Matters' PPI outreach event. The event supported engagement between the NENC population and a variety of very significant initiatives bringing innovative practice and technologies into the Healthcare system. Professor Andy Hall presented The Newcastle Molecular Pathology Node alongside two other significant initiatives -The National Institute of Health Research 'Diagnostic Evidence Collaborative', led by Professor John Simpson and The NHS England Genomics Medicine Centre and 100,000 Genomes, led by Dr Paul Brennan. The presentations covered the practicalities, myths, technologies, consent, ethics, commercial involvement in technology development and some theory around how ailments and conditions are identified and treatments decided upon. Common to all of the presentations and discussions was the virtuous circle of clinical practice informing and enabling research, the pull-through of that research into practice and the dissemination of the innovations and best practice as quickly as possible to help as many patients as possible. Plans are now being formulated to build on the success of this event with potential to take the speakers to a series of other regional events to enable further dissemination of the message. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Diagnostics North East Conference Presentation by Alastair Burt |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Video Presentation by Professor Alastair Burt at the Diagnostics NE Conference on the transformational impact digital technology is having on diagnostics and health care and the need to bring the components together into an innovation hub, such as NovoPath. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://mobile.twitter.com/novopathNCL/status/1448233788492943362 |
| Description | Doctoral Training Partnerships Event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | In October 2017, the Node hosted a DTP Molecular Pathology and Imaging training day. The day was attended by more than 50 students and included sessions on single cell genomics, pathologists approaches to immunohistochemistry and 'meet the experts' spin out discussions. The event received excellent feedback from attendees and we plan to host a similar event in 2018. |
| Year(s) Of Engagement Activity | 2017 |
| Description | EPSRC- Healthcare technologies event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The EPSRC visited the Newcastle University to host a Healthcare Technologies event. The event included a presentation from the EPSRC Healthcare Team on their strategy and recent activities as well as showcase sessions from Newcastle University on current research. The Node's bioengineering strand lead completed a presentation on his current research around developing a sensor to detect tumour margins in collaboration with Reece Innovation. The event has let to further discussions with the ESPRC and the possibility they will use the Node's bioengineering research as a case study on industry collaboration. |
| Year(s) Of Engagement Activity | 2016 |
| Description | FRC Path Training Day-May 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Then Node part funded and arranged the FRC Path Trainee day. The training day is held for local pathology trainees 3 times per year. The day included presentations of the Node, molecular pathology of infection and molecular pathology in everyday practice. The event encouraged the trainees to investigate careers is molecular pathology and provoked interest in the Node's MSc programme. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Fellow of the Royal College of Pathologists Training Day |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Then Node part funded and arranged the FRC Path Trainee day. The training day is held for local pathology trainees 3 times per year. The day included presentations of the Node, molecular pathology of infection and molecular pathology in everyday practice. The event encouraged the trainees to investigate careers is molecular pathology and provoked interest in the Node's MSc programme. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Global Business Development event-Roche |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Third sector organisations |
| Results and Impact | The Node was asked to present at a meeting of the Global Diagnostics Business Development team hosted by Roche. The event was arranged to show case the vibrant UK Life Science sector to senior and influential global delegates. The event included presentations from the Academic Health Science Networks (AHSN), National Institute Health and Care Excellence (NICE), NIHR Diagnostic Evidence Co-operatives (DEC) and the Molecular Pathology Nodes. The event helped to cement at high level the UK life sciences model and prompted possible future collaboration opportunities. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Health Economics Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Newcastle hosted a Cross-Node Health Economics workshop in May 2017. The attendees included representatives from the Node's, MRC, the NIHR DEC Newcastle and Health Economics experts. The workshops included themes trial design, informational requirements and whole disease modelling which allowed the attendees to discuss commonalities and cross-cutting issues. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Implementation guidance for carcinoma of the nasopharynx and oropharynx. Royal College of Pathologists. 19th May 2022. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | This initiative has been developed following discussion at the Working Group on Cancer Services and in response to survey findings from cellular pathologists. Members asked for more support with the implementation of our clinical guidelines, and opportunities to feedback on them to identify areas of improvement. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Industry Strategy Challenge Fund Launch Event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Event to launch the "Investment in digital pathology, radiology and AI - part of the ISCF challenge "Data to Early Diagnosis and Precision Medicine" call. Attended by industry representatives and academic partners. Led to the successful award of a Centre of Excellence in Digital Pathology and AI (led by Leeds; £10.1M) which brings together the Newcastle, Manchester and Nottingham Nodes with three other northern universities and industrial partners Roche, Leica and Sectra. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.gov.uk/government/news/artificial-intelligence-to-help-save-lives-at-five-new-technology... |
| Description | Industry workshop 'Molecular Diagnostics at Newcastle' |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The Node hosted an industry event in March 2017 that was attended by over 80 represented from Industry, NuTH and University colleagues. The purpose of the event was to bring industry together with the Node research community to identify potential collaboration opportunities around molecular diagnostics and image analysis. This sparked further discussions with commercial partners which may lead to future project work. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Informed Consent (CCB Meeting) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The National Cancer Research Institute's (NCRI) Confederation of Cancer Biobanks and the MRC Newcastle Molecular Pathology Node held a meeting entitled "Informed Consent in a Digital Age". The aim of the meeting was to bring together patients, the wider public and professional groups in order to tease apart the key issues involved in obtaining consent to use human samples in research. A series of presentations covered a broad range of related topics including; a brief background to the concepts underlying so called "fully informed" consent; the 'why' and 'how' consent is taken and the theme of appropriate timing to take consent; the experience of making contact with donor's families to request permission to obtain human tissue and; a powerful presentation from the point of view of a live organ donor. Others included the position of the regulator - the Human Tissue Authority and the importance of sample-based research; the value of modern technology to support consent and; an overview of a computer-based model of dynamic consent to enable donors to access the level of information that they require to make an "appropriately" informed decision about giving consent. The event was an opportunity for the Newcastle Molecular Pathology Node to demonstrate its ability to attract a wide audience from across the UK to debate and reaffirm the importance of human tissue collection, storage and analysis to the work of the Node and NCRI. 65 people attended in total. Useful contacts were made with colleagues from Oxford University and a follow up conference call was held to explore the potential to work together on paediatric Biobanking proposals |
| Year(s) Of Engagement Activity | 2015 |
| Description | Internatial Congress of the IAP |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Node's training strand lead (Dr Dina Tiniakos) was asked to attend the European Congress of Pathology in Cologne. The scientific programme focused on the central role of pathology and its current clinical applications, translational research, near-future innovations and the longer perspectives of paradigm shifts (integrated 'omics' care). The congress also provided a unique occasion for updating knowledge in pathology through up-to-date teaching courses highlighting news and views in diagnostic pathology. Dina was also selected to orally present one of the Node's scientific posters ' Evaluation of centrilobular fibrosis in post-transplant liver: Preliminary results' which provoked in depth discussion and promoted the Node to an international audience. |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.esp-congress.org/ |
| Description | International Academy of Pathology and Pathology Society |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | The Node had a stand at the summer meeting of the Pathology Society at Nottingham to promote the Node MSc programme. This provided a networking opportunity to promote the programme to over 400 pathologists and scientists. As a result there was a wider increase of enquiries into the Node and MSc. This also led to a joint PhD studentship with King's University Belfast. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Invited talk: "Physicians bridging Clinic and Research" |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | SFB 829 seminar series, Cologne, Germany "Physicians bridging Clinic and Research" From bench to bedside and back again: translation of inflammatory skin disease models; Sparked wide discussion about stratified medicine and mechanisms of psoriasis clearance |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://sfb829.uni-koeln.de/event/sfb-829-physicians-bridging-clinic-and-research-seminar-series |
| Description | Launch of Diagnostics North East |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Node led two thematic presentations and workshops. >180 industry, healthcare and academic delegates attended. New commercial and research leads were established. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Launch of the CEPA Biobank |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | A half day event to launch CEPA via a series of talks on the impact of high quality tissue in diagnostic development, the role of the patient in the donation process and an overview on the origins of CEPA and work to date. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Lecture Skin & Oral Disease BRC show case event |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | The full day event brought together almost 300 delegates from across the Newcastle University and Newcastle Hospitals Partnership as well as attendees from a number of North East Hospital Trusts, research funders and national and regional research infrastructure. Delegates heard a range of engaging and informative presentations from the BRC themes, as well as from the key leaders in the University and Hospital Trust Partnership and outstanding external key note speakers. Professor Avan Sayer, Director of the Newcastle BRC commented: "It was a wonderful day and inspiring to see so many people engage with our work. "From our theme leads, to our core team, students and partners, everyone was involved in preparing and making this day such a huge success. "Impact to us is about making positive changes to people's lives through our research in ageing and long-term conditions, and this event was designed to give our stakeholders an insight into some of the fantastic work that is being funded by us with these aims. "We're delighted to have had such great interest from people across the wider university and healthcare community, and we look forward to strong collaborations in the future". Participants were equally enthusiastic in their feedback, some examples include: "Really enjoyable event, great to showcase all the excellent work going on in other areas of the NIHR BRC". "It was great to see Newcastle University and Newcastle Hospitals presenting together the importance of joint working". |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.newcastlebrc.nihr.ac.uk/news/sharing-our-vision-at-the-nihr-newcastle-biomedical-researc... |
| Description | Life as a Tertiary Centre Pathologist. Pathological Society Winter Meeting. Royal Society of Medicine, London 31 January-2 February 2023. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | The aims of the event are to promote an understanding of disease through, exploration of tissues and disease models using single cell analyses, use of cutting edge microscopic and sequencing technologies, and maximising tissue interrogation by computational pathology and artificial intelligence. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.rsm.ac.uk/events/pathology/2022-23/ptr01/ |
| Description | Lunchtime seminar entitled Molecular Pathology: Future Horizons |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | In May 2017, the Node hosted a lunchtime seminar entitled 'Molecular Pathology: Future Horizons'. The guest speaker was the Director of the Institute of Pathology in Heidelberg University, Germany. The seminar was attended by over 60 people and prompted some interesting discussions around pathology and promoted the Node to a wider audience. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Medicines Discovery Catapult Launch |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | In January 2018, the Node co-director attended the Medicines Discovery Catapult's 'State of the Discovery Nation' report at MDC's headquarters at Alderley Park, Cheshire. The event provided the Node with with industry insights which will shape the future direction of drug discovery and early development in the UK. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Meet the Scientist Event-National Pathology Week |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | The Node had a stand at a 'Meet the Scientist' event for National Pathology Week at the Centre foe Life. There was several hands-on activities to deliver, while telling the general public all about pathology and the role as a pathologist. Each activity had a short introductory sign, indicating how the activities flow from cells to tissues to organs, as well as associated equipment and information cards. As the Node activities were so well received the Node plans to take part in 2017's Pathology week to increase public engagement with a younger audience. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Meeting with Histoindex |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Histoindex are a Singapore based company who have developed a novel technology for assessing tissue fibrosis in unstained slides using photonics Collaborations with various research centres, including Newcastle, have produced evidence that the method can produce robust quantitative data which correlates well with traditional morphological assessment by an experienced histopathologist. The meeting with Histoindex has led to a strengthening of the existing relationship between Histoindex and the Fibrosis department at Newcastle University. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Meeting with Sectra Ltd |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Meeting with Sectra Ltd to discuss engagement in Industry Strategy Challenge Fund Centre of Excellence in Digital Pathology and AI. Outcome was development of relationship to enable future activity and engagement in successful award of £10M funding for Leeds-led Industry Strategy Challenge Fund Centre of Excellence in Digital Pathology and AI. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Molecular Diagnostics at Newcastle-Node Industry Event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The Node was asked to take part in the Newcastle University NAHP Industry Month with a day-long event to showcase Node-related work. The title for the event was 'Molecular Diagnostics at Newcastle' and it was held on the 2nd March 2017. The purpose of the event was to bring industry together with the Node research community to identify potential collaboration opportunities around molecular diagnostics and image analysis. The day involved presentations on current Node research (both biomedical and image analysis) as well as a slot on Tissue Access and the new CePa biobank which the Node will collaborate with. Excellent feedback was received for the event which included attendees from an array of industries as well as key business development managers from the Trust and University. The event has led to several possible collaboration opportunities with potential industry partners. |
| Year(s) Of Engagement Activity | 2016 |
| Description | NCRI Cancer Conference Liverpool |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Node had a stand at the NCRI Conference in Liverpool to promote the Node Clinical Sciences and Pathology MSc Programme. As a result there was a wider awareness of the programme and several enquiries were received from potential students. |
| Year(s) Of Engagement Activity | 2016 |
| Description | NCRI Confederation of Cancer Biobanks- Glasgow |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | CCB and CM-Path held a joint meeting in Glasgow on 17 October, on "working together" to maximise opportunities. The CCB has always shared best practice in a climate of mutual support. This is as important as ever in the rapidly changing biobanking landscape. The programme presentations from representatives of the CM-Path initiative, Newcastle Molecular Pathology Node, BBMRI-ERIC and the UKCRC Tissue Directory and Coordination Centre. A pre-meeting for this event also took place in Glasgow between the Node Project Director and Project Manager in which the agenda was set and the launch of the CRUK directory was discussed. |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.biobankinguk.org/working-together-collaboration-in-the-cancer-biobanking-landscape/?mc_c... |
| Description | Newcastle Diagnostic Evidence Co-operative 'Adopting MedTech' Event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The Node participated in a 'soft launch' at the Diagnostic Evidence Co-operative's (DEC) 'Adopting MedTech' event at the Centre for Life. The industry-focussed event presented an opportunity to talk about the Node within the unique regional context of the North East, the only region with both a MRC Node and NIHR DEC. Presenting a coherent 'offer' to industry is often cited as an unmet challenge and this event was aimed at addressing this. The Node had a well-supported stand in the networking area with colleagues from Cellular Pathology and BioEngineering on-hand to meet with delegates to discuss the Node and take contact details; there was a Q&A Panel where the Node was represented by Professor Phil Sloan - the Node Pathology Lead, and the Node was included in the conference programme including a biography of Professor Sloan and a section of the Node and its objectives. The event was well attended with over 100 local and national delegates. The outcome was the collection of contact details which are being followed up, including a specific request for sample access from a key industrial partner and a telephone interview to discuss collaborative research opportunities. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Node Director's Event |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | In February 2018, the Newcastle Node hosted a directors event which included representatives from all Node's and the MRC. The purpose of the event was to share progress, discuss challenges and individual plans for future sustainability. The event prompted interesting discussions and the possibility of joint funding applications to the Industry Strategy Challenge fund. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Node Director's event - 10th January 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | In January 2017, the Newcastle Node hosted a Node Director's event at the Centre for Life. The event was attended by the Node Directors and Project Managers from Glasgow, Manchester, Edinburgh, Nottingham and Leicester. It was also attended by a representative from the MRC and CM Path. The event aimed to build on the existing Node network by allowing the Node's to share their achievements and challenges through the first year of the project. There was also the discussions around Node sustainability and business planning beyond the current MRC grant award. The event prompted discussions into joint funding applications and has led to another Newcastle Node Director's event being arranged for November 2017. |
| Year(s) Of Engagement Activity | 2016,2017 |
| Description | Node Project Managers Meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Manchester Molecular Pathology Node hosted the first meeting of the MRC/EPSRC Molecular Pathology Node Manaagers' at Manchester University. All 6 Nodes were represented. Each presented an overview of their work strands, research themes and partners. The event provided an excellent oppotunity to agree how the network of Nodes will complement each other and work together. The outcome has been the establishment and further development of collaborative opportunities between the Newcastle and Manchester Node on both tissue sample access and training. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Node Sustainability workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | The MRC/EPSRC Molecular Pathology Node grant ended 31st August 2019 and we found ourselves in a transitional period where we could reflect on our achievements and experiences to date and look to the continued growth and success of the Node. Invites were welcomed for their input into this process during a 2 hour workshop with the aim of bringing together business leads, investigators and Node collaborators to discuss the future of the project within the broader context of Precision Medicine. The aim of the meeting was to affirm progress on sustainability planning and proposed delivery structures and to identify areas of development which could support future collaborative working. Professor Alastair Burt delivered a presentation with some potential ideas covering a broader strategic development aimed at being the "innovation Hub" for tissue based diagnostics in Newcastle (and beyond). The outcome of the meeting supported the development of a 5 year Node business plan and growth strategy which was delivered at the end of March 2020. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Node Training Workshop- Liverpool |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | In November 2017, the Node project officer and training representative attended the Node training network workshop in Liverpool. The workshop gave the Node network the opportunity to discuss individual programmes, networking with other external bodies to influence national training and the potential of accreditation with the Royal College of Pathologists. |
| Year(s) Of Engagement Activity | 2017 |
| Description | NovoPath Presentation by Prof Burt to Newcastle in Vitro Diagnostics Co-operative (MIC) Group |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Overview presented by Professor Alastair Burt on the history, current and future of NovoPath - The Newcastle MRC Node. This presentation was requested by the Newcastle in Vitro Diagnostics Co-operative (MIC) Group to gain a better understanding of the services provided and the future of the Project. During the presentation there was interaction with all members and feedback was positive with potential collaboration with future projects. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.novopath.co.uk |
| Description | OK to Ask-PPI event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | A Public & Patient Involvement event, which included 14 patient representatives from the Perspective group & the Cancer Research group, was held on the 15th August in the Maggie's Centre. This was also attended by a small group of NHS staff, the Newcastle Molecular Pathology Node and a HTA Regulatory Manager. The agenda for this meeting was to gain patient perspectives' on the benefits to healthcare for collaboration between NHS and commercial partners' in particular regarding the supply of tissue from the NHS to commercial companies on a cost recovery basis. The public provided a positive response to the proposal which has led to the creation of a Node supported Biobank in the Cellular Pathology Department of the RVI in Newcastle. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Oncology workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oncology Workshop - showcasing our expertise in Oncology / Cancer research, and including NHS Observer Status to enable Industry representatives to attend NHS Clinics. Collaborations with industry were strengthened (new and existing relationships); 17 engaged external partners attended. Actively engaged in follow-on activities with partners. Poster / informal networking session gave attendees the opportunities to meet with ECRS, PG students, and the broader Newcastle Institute for Cancer Research community. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Presentation on the Future of Precision (Tissue-Based) Dianostics in Newcastle |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | This presentation was given to Executive members for both Newcastle University and Newcastle upon Tyne Hospital. The content outlined a clear vision and mission to deliver innovation and promotion of precision diagnostics. The mission included technical services, innovation hub, development and equipment for the next generation of precision pathology, which would become a major strand of Diagnostics NE and a Centre of Excellence. Ambitious target growth was planned with an increase of 300% in turnover over 5 years. 23 recommendations were outlined, with anticipated timescales assigned. These included an Advisory Panel with key stakeholders from industry being involved, identification of Deputy Node Directors, an accountability framework and the improvement of a commercialisation strategy including the launch of a new/updated website. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.novopath.co.uk |
| Description | Proximity to Discovery Dermatology/Rheumatology workshop |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Dr Amy Peasland, Newcastle Biobank Central Biobank Manager, presented an overview of the Newcastle Molecular Pathology Node at a workshop of potential industry partners during the Dermatology and Rheumatology MRC Proximity to Discovery (PtD) programme. The event was aimed at showcasing the excellent biomedical resources and facilities available in Newcastle and specifically considered issues such as combining basic research and clinical investigation in order to explore translational science; stratified medicine; training of the next generation of researchers and; collaborative working between industry and academia. The workshop was held within a programme which encompassed themed lectures and a variety of specialist clinics and open discussions with patients and clinical staff on unmet clinical needs. The Node was positioned within the context of biobanking and sample access opportunities and contact was established with key industrial representatives from GSK, AbbVie, Roche, Lily, Novartis and Nascient. The PtD week was organised by the Faculty of Medical Sciences at Newcastle University during their 'Industry Month' of activities. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Seminar Workshop 'Beyond the Microscope' Professor Simon Herrington, Edinburgh University. January 2022. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | NovoPath in conjunction with Eli Lilly held a seminar workshop with guest speaker Professor Simon Herrington. Professor Herrington discussed the future of pathology. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.novopath.co.uk/wp-content/uploads/2021/12/2201-Newcastle-Herrington.pdf |
| Description | Seminar Workshop 'Optical Genomic Mapping with the Bionano Saphyr - Gavin Cuthbert, Cancer Lead - Newcastle NHS Genetics Laboratory - November 2022 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Seminar workshop held by NovoPath with guest speaker Gavin Cuthbert around the evaluation of the clinical utility of optional genomic mapping in diagnostic haemato-oncology. Discussion around optical genome mapping using the Bionano Saphyr. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.novopath.co.uk/wp-content/uploads/2022/10/NovoPath-seminar-2.11.22-gc.pptx |
| Description | Seminar Workshop 'Roche Digital Pathology with UPath image analysis and Interpretation algorithms' - Connor Roddie, Sales Specialist - Roche Tissue Diagnostics . October 2022 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Seminar workshop supported by NovoPath with guest speaker Connor Roddie on Roche Digital Pathology, empowering precision diagnosis. Gave the Department and staff of NovoPath further insight into the use of Roche digital software and sparked further information to be sought around this. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.novopath.co.uk/wp-content/uploads/2022/10/SWLP-Vision-Day-Digital-Pathology-Daniel-Plews... |
| Description | Seminar Workshop 'The Business of Pathology' Colin Tristram, HistoCyte Laboratories Ltd. May 2022. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | NovoPath in conjunction with Eli Lilly presented a virtual lecture with guest speaker Colin Tristram around the Business of Pathology. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.novopath.co.uk/wp-content/uploads/2022/05/The-Business-of-Pathology_MAY22.pdf |
| Description | Seminar Workshop - MR 'Pathologists and Clinical Trials' June 2022 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | NovoPath, in conjunction with Eli Lilly, hosted a virtual lecture with guest speaker Dr Max Robinson - Pathologists and Clinical Trials. Gave an insight into SPIRIT Path and opened up questions around this, pathology and clinical trials. Highlighted the presence of NovoPath to the wider audience. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.novopath.co.uk/wp-content/uploads/2022/06/2021-SPIRIT-Path-NovoPath.pptx |
| Description | Seminar Workshop - National Pathology Imaging Co-operative: 'Digital Pathology in the North and beyond' Dr Darren Treanor, Consultant Pathologist & Director, NPI. February 2022. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Seminar workshop supported by NovoPath with guest speaker Dr Darren Treanor around Digital Pathology in the North and beyond. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Stratified Medicine Network event, 'Re-engineering of clinical pathways to facilitate implementation of personalised medicine' |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The Node sent two representatives the stratified medicine networking event which was well attended by NHS representatives, academics, patients, industry and members of the general public. Some of the talks at the event provoked discussion into the fact that individualised treatment will require substantial re-modelling of established care pathways and the role that NHS England must play in leading this. Valuable contributions from patients pointed out that 'personalised medicine' means a lot more than understanding the genetic basis of their condition. Being valued and cared for as an individual is extremely important, and so from their point of view improvements to medical record systems to allow clinical staff from different organisations, such as different Trusts and GP practices was as important as improvements to diagnostics and treatments, as was being cared for by experienced staff who were familiar with appropriate best practices for patients such as themselves. It was noticed that gaining as much useful healthcare information from other patients with similar conditions as they obtained from healthcare professionals. Following on from this event the Node agreed to attend further stratified medicine networking events to engage with the public and patients. |
| Year(s) Of Engagement Activity | 2016 |
| Description | TC with Phillips |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Teleconference with Phillips to discuss engagement in Industry Strategy Challenge Fund Centre of Excellence in Digital Pathology and AI. Outcome was development of relationship to enable future activity. |
| Year(s) Of Engagement Activity | 2018 |
| Description | TC with Siemens |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Teleconference with Siemens to discuss engagement in Industry Strategy Challenge Fund Centre of Excellence in Digital Pathology and AI. Outcome was development of relationship to enable future activity |
| Year(s) Of Engagement Activity | 2018 |
| Description | Taking biomarker discovery through to implementation - presentation at BIONOW Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Bionow is a not for profit membership organisation supporting the biomedical, pharma and life sciences sectors across the North of England. Bionow does this by bringing people together at our exciting conferences and events across the North, being an advocate for the North, and providing comprehensive procurement member benefits that strengthen the competitiveness of the North's innovative life science sector. This presentation formed part of one of their regular events aimed at increasing awareness of the sector. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.bionow.co.uk/ |
| Description | Teleconference with GE Healthcare |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Teleconference with GE Healthcare to discuss engagement in Industry Strategy Challenge Fund Centre of Excellence in Digital Pathology and AI. Outcome was GE Healthcare engagement with Newcastle Hospitals Radiography bid for a Centre of Excellence and building of relationships for future collaboration. |
| Year(s) Of Engagement Activity | 2018 |
| Description | UK Stratified Medicine Event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The UK Stratified Medicine Conference was organised by the Stratified Medicine Innovation Platform Programme Coordination Group consisting of the Academy of Medical Sciences, Arthritis Research UK, Cancer Research UK, Department of Health, Innovate UK, Knowledge Transfer Network, MHRA, MRC, NICE, NIHR, NHS England, UK Trade and Investment, Welsh, Scottish and Northern Ireland Governments. The aim was of the group is to help ensure that, through coordinated action, the UK has the right environment to capture the patient and economic benefits offered by stratified medicine. Participation was an opportunity for the Newcastle Molecular Pathology Node to showcase its involvement in facilitating the development of novel approaches to treatment stratification and training opportunities for staff involved in molecular pathology. Useful contacts were made with other partners involved in the evolving funding landscape, such as the Precision Medicine Catapult and other Molecular Pathology Nodes. |
| Year(s) Of Engagement Activity | 2015 |
| Description | UK TREND / Stratified Medicine follow-on Meeting, London |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | UK TREND Atopic Eczema Stratified Medicine follow-on meeting (hosted at the British Association of Dermatologists (BAD) in London). This second workshop, convened to strengthen the work of the first workshop in specific areas, has resulted in more carefully defined work streams, and led to a greater understanding of the potential contributions from collaborators (including Pharma). Collaborations with industry were strengthened (both new and existing relationships); 7 fully engaged industrial partners attended, along with 3 patient representatives, and 18 potential collaborators from other UK Universities and the NHS. Five companies were represented - Sanofi, GSK and Croda (UK), LEO Pharma (1 delegate from Denmark) and Abbvie (3 delegates from US). Expertise was shared and feedback was extremely positive (93% of the feedback graded the meeting as 'very useful' 5/5 overall). The aim of the initiative is to develop a consortium with which to gain funding to further develop projects, and this is ongoing. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Visit - Kristen McLeod, Director, Office of Life Sciences |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | The Node and CEPA were selected as exemplar projects by the NuTH Executive Director of Business and Development. Ms McLeod toured the Proximity Lab and met our commercial partners. Outcome was to influence national policy and funding strategies around life sciences. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Visit - President of RCPath, Professor Jo Martin |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prof. Martin toured the Proximity Lab and met Node team members on a recent visit to Cellular Pathology. Outcome to influence Royal College of Pathology engagement and national strategic direction. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://twitter.com/JoMartin_path/status/1027246410612334593 |
| Description | Visit of Lord Henley, Minister for Business, Energy & Industrial Strategy |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Visit by senior policy maker to Cellular Pathology Department at RVI Hospital, Included Proximity Lab tour and industrial partnership showcase with Leica. Outcome was agreement for Lord Henley to influence policy and funding plans. Audience included AHSN. |
| Year(s) Of Engagement Activity | 2018 |